Multi-Biomarker Composite for Early Detection of Neurodegenerative Disease

Computational Score: 0.850 Price: $0.50 Alzheimer disease Retrospective analysis of existing clinical cohort datasets (ADNI, BIOFIND) Status: proposed

What This Experiment Tests

Computational experiment designed to assess clinical efficacy targeting N/A in Retrospective analysis of existing clinical cohort datasets (ADNI, BIOFIND). Primary outcome: AUC-ROC diagnostic accuracy and cognitive decline prediction variance explained

Description

Develop and validate a multi-biomarker composite index (combining plasma p-tau217, NfL, GFAP, and additional markers) that outperforms amyloid PET for early detection of neurodegeneration and treatment response prediction.

TARGET GENE
N/A
MODEL SYSTEM
Retrospective analysis of existing clinical cohort datasets (ADNI, BIOFIND)
ESTIMATED COST
$28,000
TIMELINE
6 months
PATHWAY
N/A
SOURCE
auto-generated
PRIMARY OUTCOME
AUC-ROC diagnostic accuracy and cognitive decline prediction variance explained

Scoring Dimensions

Info Gain 0.82 (25%) Feasibility 0.78 (20%) Hyp Coverage 0.88 (20%) Cost Effect. 0.75 (15%) Novelty 0.80 (10%) Ethical Safety 0.00 (10%) 0.850 composite

Protocol

computational

Expected Outcomes

Composite biomarker index achieves AUC > 0.90 for AD vs. controls (vs. <0.80 for amyloid PET alone) and explains >60% of variance in longitudinal cognitive decline.

Success Criteria

AUC-ROC for diagnostic discrimination; linear mixed model R² for cognitive decline prediction; threshold: composite AUC > 0.90 and R² > 0.60.

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.